Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from EXEL

3 Biotech Stocks to Buy Instead of Palatin Technologies (PTN)

While Palatin Technologies (PTN) has faced challenges with declining share price, negative analyst projections, and limited profitability, it's worth noting the consistent growth in the broader biotech industry. Thus, investors could find more stable returns in robust biotech stocks Protalix BioTherapeutics (PLX), Exelixis (EXEL), and Jazz Pharmaceuticals (JAZZ) instead. Read…

StockNews.com

3 Biotech Stocks Offering Potential for Gains

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus, it could be wise to invest in fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Shionogi (SGIOY), and Exelixis (EXEL)for potential gains. Read on….

StockNews.com

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

With the rising aging population and the emergence of new diseases, the biotech industry appears poised for steady growth. Therefore, three quality biotech stocks, Vanda Pharmaceuticals (VNDA), Organogenesis Holdings (ORGO), and Exelixis (EXEL), could be better catches than Bionano Genomics (BNGO). Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Top 3 Biotech Stocks to Watch and Buy for Healthy Profits

With innovative approaches and cutting-edge technologies, biotech has ushered in a new era of possibilities in the medical field. Hence, investing in three fundamentally sound biotech stocks, Equillium, Inc. (EQ), Theratechnologies (THTX), and Exelixis (EXEL), could yield healthy profits. Learn more….

StockNews.com

3 Biotech Stocks With Great Value

The global demand for healthcare and biotech products continues to grow, owing to factors such as increasing chronic diseases and a greater focus on personalized medicine. Therefore, it might be wise to check out fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Exelixis, Inc. (EXEL), and Theratechnologies (THTX), currently trading at…

StockNews.com

2 Explosive Biotech Stocks to Own

The biotech industry is well-positioned to grow, thanks to breakthrough advances, rising chronic illness and government support. So, fundamentally solid biotech stocks, Genmab (GMAB) and Exelixis (EXEL) may be worth buying now. Read on.

StockNews.com

3 Biotech Stocks Losing Momentum

As March comes to an end, biotech stocks Exelixis (EXEL), MacroGenics (MGNX), and Puma Biotechnology (PBYI) have been losing momentum. However, given the long-term prospects of the biotechnology industry and the administration’s push to boost domestic biomanufacturing, these biotech stocks could prove to be solid long-term investments. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

4 Biotech Stocks You Don’t Want to Miss out on in 2023

The biotech industry is growing with considerable developments and government initiatives. Given the solid prospects of the industry, fundamentally sound biotech stocks Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Exelixis (EXEL), and Cidara Therapeutics (CDTX) could be excellent buys. Keep reading.

StockNews.com

5 Biotech Stocks That Could Make You Rich in 10 Years

The biotech industry is rapidly growing amid rising private and government investments and technological advancements. Given the solid prospects of the industry, fundamentally strong biotech stocks Amgen (AMGN), Vertex (VRTX), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be ideal long-term investments for steady returns. Keep reading.

StockNews.com

4 Biotech Stocks to Keep an Eye on in 2023

The U.S. 2022 fourth-quarter GDP growth surpassed estimates and induced fresh optimism. On the other hand, the biotech industry is expected to witness robust demand despite macro uncertainties. So, given the stable prospects of the biotech sector, quality stocks Amgen (AMGN), BioNTech (BNTX), Exelixis (EXEL), and Taisho Pharmaceutical (TAIPY) could…

StockNews.com

Manufacturing giant Exel Composites puts 50 jobs at risk in bid to save millions

The company said it could save €1.6m a year if it goes ahead with the plans

Liverpool Echo

Almost 50 jobs at risk at industrial manufacturer Exel Composites as it considers downsizing UK operations

Exel Composites employs approximately 650 members of staff around the world and is listed on Nasdaq Helsinki

Birmingham Post

3 Biotech Stocks to Buy for Under $20 Right Now

The need for more advanced biotech research and development has increased amid an aging population and growing medical needs. Investors' sentiment toward biotech stocks has improved significantly over the past months. Given the industry's solid prospects, fundamentally sound biotech stocks Exelixis (EXEL), Innoviva (INVA), and Cidara Therapeutics (CDTX) might be…

StockNews.com

2 Stocks to Buy at a Discount Right Now

Better-than-expected corporate earnings and growth in the services sector last month should help offset the impact of recession fears on the stock market. However, since market swings are expected to continue, it could be wise to invest in quality stocks Exelixis (EXEL) and AutoNation (AN), currently trading at significant discounts…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Exelixis-BioInvent Establish Immuno-Oncology Pact

Exelixis Inc (NASDAQ:EXEL) and BioInvent International AB (OTC:BOVNF) have entered into an option and license agreement focused on identifying and developing novel antibodies for use in immuno-oncology therapeutics. Exelixis will pay BioInvent an upfront fee of $25 million in exchange for rights to select three targets identified using BioInvent's proprietary F.I.R.S.T platform and n-CoDeR library. …

StockNews.com

Buy the Dip: 2 Growth Stocks to Add to Your Portfolio

Escalating fears over inflationary pressures, the Federal Reserve’s tighter monetary policy, and slow economic growth have caused a massive sell-off in growth stocks over the past few weeks. But the recent sell-off has created an attractive buying opportunity for long-term investors. So, we think it could be profitable to buy…

Benzinga

Exelixis: Q1 Earnings Insights

Exelixis (NASDAQ:EXEL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by 85.71%, reporting an EPS of $0.26 versus an estimate of $0.14.

Benzinga

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer

The European Commission (EC) has approved Ipsen SA's (OTC:IPSEY) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting. The approval covers adult patients with locally advanced or metastatic DTC, refractory or not eligible for radioactive iodine, who have progressed during or after systemic therapy. This EC approval follows the FDA approval announced…

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Outperforming Biotech Stocks with More Room to Run

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

Benzinga

EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer

Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have

Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus atezolizumab versus sorafenib in untreated hepatocellular carcinoma (HCC).

StockNews.com

4 Outperforming Growth Stocks to Buy in March

The United States economy is growing strongly, outperforming other developed economies. Furthermore, analysts believe the country is well-positioned to weather economic challenges created by the Russia-Ukraine war. So, we think that growth stocks Vertex Pharmaceuticals (VRTX), Fair Isaac (FICO), Ralph Lauren (RL), and Exelixis (EXEL), which have outpaced the broader…

StockNews.com

2 Undervalued Biopharmaceutical Stocks to Scoop Up in February

Biopharma stocks have been trading at lower valuations because of uncertainties surrounding drug-pricing reform, regulatory surprises, and COVID-19. However, the biopharma industry is expected to grow in the coming years. Given the bullish analysts’ sentiment around the sector, biopharma stocks Gilead (GILD) and Exelixis (EXEL), which look undervalued at their…

Benzinga

Exelixis: Q4 Earnings Insights

Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by 483.33%, reporting an EPS of $0.35 versus an estimate of $0.06.

Benzinga

Earnings Preview For Exelixis

Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will report an earnings per share (EPS) of $0.06.

1 2 3

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.